ClinicalTrials.gg
RecruitingNCT06801899ToPancUpdated Aug 12, 2026

ToPanc Trial: Survival After Total Versus Partial Pancreaticoduodenectomy for Adenocarcinoma of the Pancreatic Head, Distal Cholangiocarcinoma, and Ampullary Cancer

An interventional study of Total pancreatectomy (TP) and Partial pancreaticoduodenectomy (PD) in Pancreatic Cancer, sponsored by Insel Gruppe AG, University Hospital Bern. Recruiting at 10 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-12.

Sponsored by Insel Gruppe AG, University Hospital Bern · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
170
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 58 studies in Pancreatic Neoplasms with a site in Switzerland — 9 open to participants now, 11 under way, 3 of them phase 3. Pancreatic Neoplasms · Switzerland.

Planned enrollment
16th of 47
170 · median 97
Started
2026
with 4 others
No phase
7 of 58
3 open now
Primary completion
2030-10
later than 10 of 10 live
Registered
52nd of 58
by date
Lead sponsor
4 of 58
Insel Gruppe AG, University Hospital Bern

Among the 58 studies in Pancreatic Neoplasms with a site in Switzerland, this one is the 16th largest by planned enrollment of the 47 interventional ones that give a count, is one of 5 that started in 2026, is one of 7 with no phase, reaches primary completion later than 10 of the 10 other live ones, and was the 52nd registered.

Pancreatic Neoplasms

3,903 studies on the registry are indexed under Pancreatic Neoplasms; 1,005 are open to participants now.

Browse Pancreatic Neoplasms studies →

Open to participants now

9 of the 58 studies in Pancreatic Neoplasms with a site in Switzerland are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 743 Pancreatic Neoplasms studies recruiting now, 476 (64%) set no upper age limit and 153 (21%) stop at 75 or younger; 40 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 58 studies in Pancreatic Neoplasms with a site in Switzerland, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if total removal of the pancreas is a preferable alternative to partial removal in patients with cancer of the pancreatic head who are at high risk of pancreatic leakage. The main question it aims to answer is:

Does total pancreas removal improve survival without reducing quality of life compared to partial removal?

The only study specific procedures are the collection of 2 blood samples (7.5ml for each time point, preoperatively and during the hospitalisation) and the completion of the questionnaires.

Read the detailed description

The pancreas is located in the upper abdomen and has 2 main functions: Production of digestive juices and of insulin, the latter being most important for blood sugar regulation and energy conservation. Certain types of cancer in the pancreatic head are very aggressive, but with complete surgical removal of the tumor and additional chemotherapy cure is possible. For tumor resection, the head of the pancreas as well as duodenum and part of the bile duct are removed. 3 new connections are built: the remaining pancreas, bile duct and stomach are connected to a loop of small intestine.

This operation takes around 6 hours and leads to complications in 20-30% of cases. A serious complication and unfortunately the most frequent is the leaking of the pancreas remnant, with outflow of the aggressive digestive juice into the surrounding tissue. Consequences may be severe bleeding and/or infections. Many studies show that affected patients have an increased risk of tumor recurrence and a reduced survival.

To avoid pancreatic leak, the entire pancreas can be removed. So far, removal of the whole pancreas has only been chosen in cases of very advanced cancer. After both, partial or total pancreas removal, patients need to substitute digestive enzymes. This can be done by capsules, which need to be taken with every meal. But while some patients after partial removal maintain sufficient function to produce insulin, all patients after total removal are diabetic and need insulin injections. In the past, blood sugar control in the absence of insulin production was difficult and accompanied by low quality of life (QoL). This has changed tremendously by the introduction of continuous glucose monitoring (sensors, which are attached to the arm) and automated insulin delivery systems (also known as "artificial pancreas"). This development renders total pancreas removal a reasonable alternative, with the advantage, that only 2 new connections are made: One between the bile duct and small intestine and one between the stomach and the small intestine.

Study question: Is removal of the whole pancreas in patients at high risk of a pancreatic leakage a preferable alternative to partial removal?

For this study, patients with cancer of the pancreatic head who are planned for surgery can be included. These patients will be randomly assigned to two groups:

  1. Standard group: partial removal of the pancreas
  2. Study group: total removal of the pancreas

Both techniques are safe and are established techniques to treat cancer in the pancreatic head. After the operation, many clinical data will be recorded. The two most important factors will be survival and quality of life, which will be assessed by questionnaires on a regular base. Additionally, postoperative complications, chemotherapy rates, tumor recurrence and many more data will be monitored.

03

Conditions studied

  • Pancreatic Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients (age ≥ 18 years) scheduled to undergo PD for highly suspected or proven, resectable pancreatic ductal adenocarcinoma (PDAC), distal cholangiocarcinoma (DCC), and/or ampullary cancer (pancreaticobiliary type)
  • Suspected pancreas anastomosis at high-risk for development of a postoperative pancreatic fistula (POPF) (grade "D" according to Schuh et al. (29): Estimation by CT scan, MRI, and/or Endoscopic Ultrasound
  • Written

Exclusion criteria

Exclusion Criteria:

  • Duodenal carcinoma, ampullary cancer (intestinal type), neuroendocrine tumors, benign tumors, chronic pancreatitis
  • Medical conditions that do not allow appreciation of the nature, scope, and possible consequences of the trial as judged by the investigator
  • Pregnancy. A beta-Human Chorionic Gonadotropin (bHCG) pregnancy test must to be performed for women of (defined as premenopausal women who have not undergone surgical sterilization)
  • Inability to follow the study procedures, e.g., due to psychological disorders, dementia, etc.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
170 participants (estimated)

Study arms

  • Experimental
    Total pancreatectomy (TP)

    Procedure: Total pancreatectomy (TP)

  • Active comparator
    Pancreaticoduodenectomy (PD)

    Procedure: Partial pancreaticoduodenectomy (PD)

Interventions

  • ProcedureTotal pancreatectomy (TP)

    The investigators perform TP in patients who undergo surgical resection of a malignant tumor in the pancreatic head.

  • ProcedurePartial pancreaticoduodenectomy (PD)

    The investigators perform partial PD with anastomosis of the pancreas in patients who undergo surgical resection of a malignant tumor in the pancreatic head. This is the current standard procedure.

06

What researchers measure

Primary outcomes

  1. Overall survival (OS)

    Number of participants who survived for 2 years after surgery.

    Time frame: At 2 years

Secondary outcomes

  1. Quality of Life (QoL) Pancreatic Cancer

    Recorded as participant-reported outcome. Measured by European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire for pancreatic cancer (EORCT QLQPAN26). Scale from 0 to 104, with higher scores indicating a greater level of symptoms or problems.

    Time frame: At 0.5 year, at 1 year, at 2 years

  2. Quality of Life (QoL) Diabetes

    Recorded as participant-reported outcome. Measured by Diabetes Distress Scale (DDS) 17 Questionnaire (only for patients with insulin-dependent diabetes). Scale from 17 to 102, with higher scores indicating a greater level of distress.

    Time frame: At 0.5 year, at 1 year, at 2 years

  3. Postoperative complications (discriminating minor and major complications)

    Number of participants with postoperative complications. Classified according to the Clavien-Dindo-classification (major complication defined as Clavien-Dindo Grade ≥ III).

    Time frame: Within 90 day of surgery

  4. Mortality

    Number of participants who died.

    Time frame: Within 90 days of surgery

  5. Length of hospital stay in days

    Time frame: Within 90 days of surgery

  6. Re-admission

    Number of participants who were re-admitted to the hospital.

    Time frame: Within 90 days of surgery

  7. Re-operation

    Number of participants who required a re-operation.

    Time frame: Within 90 days of surgery

  8. Adjuvant Chemotherapy (ACT) initiation

    Number of days from surgery to ACT initiation.

    Time frame: At 1 year

  9. Adjuvant Chemotherapy (ACT) completion

    Number of days from surgery to ACT completion.

    Time frame: At 1 year

  10. Disease-Free Survival (DFS)

    Number of participants who remained free of disease. Defined as no new metastasis or local recurrence on CT or MRI imaging, and, if applicable, laboratory tests (new Ca19-9 increase).

    Time frame: At follow-up, up to 4.5 years

  11. Functional status

    Recorded as participant-reported outcome. Measured by Eastern Cooperative Oncology Group (ECOG) Performance Status Scale. Scale from 1 to 5, with higher scores indicating a greater level of disability.

    Time frame: At 0.5 year, at 1 year, at 2 years

  12. Body Mass Index (BMI)

    Time frame: At 0.5 year, at 1 year, at 2 years

07

Study locations

10 of 10 sites recruiting
  • Department of General, Visceral and Transplantation Surgery, University Hospital Münster
    Münster, 48149, Germany
    Recruiting
  • Department of General and Visceral Surgery, University Hospital Ulm
    Ulm, 89081, Germany
    Recruiting
  • Department of General and Visceral Surgery, Kantonsspital Aarau
    Aarau, 5001, Switzerland
    Recruiting
  • Department of Surgery, Kantonsspital Baden
    Baden, 5404, Switzerland
    Recruiting
  • Department of Visceral Surgery, University Hospital Basel
    Basel, 4031, Switzerland
    Recruiting
  • Inselspital, Bern University Hospital
    Bern, 3010, Switzerland
    Recruiting
    • Anna S Wenning, MD, PhD · Contact
    • Anna S Wenning, MD, PhD · Principal investigator
  • Department of Visceral Surgery, University Hospital Geneva
    Geneva, 1205, Switzerland
    Recruiting
  • Department of General, Visceral, Endocrine and Transplantation Surgery, Kantonsspital St. Gallen
    Sankt Gallen, 9000, Switzerland
    Recruiting
  • Department of Surgery, Stadtspital Triemli Zürich
    Zurich, 8063, Switzerland
    Recruiting
  • Department of Surgery and Transplantation, University Hospital Zürich
    Zurich, 8091, Switzerland
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Oct 2030, 52 months after the start.

Of 405 non-industry interventional studies with no phase under Pancreatic Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 75. This study's planned 52 months is above that.

Counting every sponsor, half of 432 studies reached it within 44 months; a quarter within 26 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 24, 2025
First posted
Jan 30, 2025
StartActual
Jun 1, 2026
Primary completionEst.
Oct 2030
CompletionEst.
Oct 2030
Last update
Aug 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06801899
Responsible party
Sponsor
First posted
Jan 30, 2025
Start date
Jun 1, 2026
Primary completion
Oct 2030 (estimated)
Completion
Oct 2030 (estimated)
Last update
Aug 12, 2026

Study contacts

Anna S Wenning, MD, PhD
Contact
annasilvia.wenning@insel.ch
+41 (0)31 632 71 41
Nadine Uebersax
Contact
nadine.uebersax@unibe.ch
+41 (0)31 684 33 69
Anna S Wenning, MD, PhD
principal investigator · Department of Visceral Surgery and Medicine Inselspital, Bern University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion